Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 188
Filter
2.
Oncogene ; 26(53): 7457-66, 2007 Nov 22.
Article in English | MEDLINE | ID: mdl-17546045

ABSTRACT

Both genotoxic and oncogenic stress activates the nuclear factor-kappa B (NF-kappaB) and p53 proteins; however, the p53 activity is antagonized by NF-kappaB signaling. Dmp1 is a Myb-like transcription factor that activates the Arf-p53 pathway. The Dmp1 promoter was activated by a classical NF-kappaB activator tumor necrosis factor alpha, but repressed by treatment of cells with non-classical NF-kappaB activators, anthracyclins and UV-C. p65 and other subsets of NF-kappaB proteins were bound to the Dmp1 promoter following anthracyclin/UV-C treatment of rodent fibroblasts. This resulted in the downregulation of Dmp1 mRNA and protein. Repression of the Dmp1 transcription by anthracyclins depended on the unique NF-kappaB site on the promoter. Downregulation of p65 significantly attenuated the repression of the Dmp1 promoter by anthracyclins/UV-C. The amount of Dmp1 bound to the Arf promoter decreased significantly upon anthracyclin treatment; this, in turn, downregulated the Arf levels. Repression of the Arf promoter by p65 or anthracyclins depended on Dmp1, which was significantly attenuated in Dmp1(-/-) cells. Both Dmp1(-/-)and Arf(-/-)cells showed resistance to anthracyclin-induced cell death compared to wild-type cells; non-immortalized p65-knockdown cells were much more sensitive. Thus, the Dmp1-Arf pathway is repressed by p65 in response to genotoxic stress, which implicates a novel mechanism of p53 inactivation by NF-kappaB.


Subject(s)
Anthracyclines/pharmacology , Cyclin-Dependent Kinase Inhibitor p16/genetics , Extracellular Matrix Proteins/genetics , Transcription Factor RelA/physiology , Transcription, Genetic/drug effects , 3T3 Cells , Animals , Cyclin-Dependent Kinase Inhibitor p16/biosynthesis , Daunorubicin/pharmacology , Down-Regulation , Doxorubicin/pharmacology , Extracellular Matrix Proteins/biosynthesis , Gene Expression Regulation , Mice , NF-kappa B p50 Subunit/genetics , NF-kappa B p50 Subunit/metabolism , Promoter Regions, Genetic/drug effects , RNA, Messenger/biosynthesis , RNA, Messenger/genetics , Transcription Factor RelA/genetics , Transcription Factor RelA/metabolism , Tumor Necrosis Factor-alpha/pharmacology
3.
Oncogene ; 26(30): 4329-35, 2007 Jun 28.
Article in English | MEDLINE | ID: mdl-17237816

ABSTRACT

Dmp1 (cyclin D binding myb-like protein 1; also called Dmtf1) is a transcription factor that was isolated in a yeast two-hybrid screen through its binding property to cyclin D2. Although it was initially predicted to be involved in the cyclin D-Rb pathway, overexpression of Dmp1 in primary cells induces cell cycle arrest in an Arf, p53-dependent fashion. Dmp1 is a unique Arf regulator, the promoter of which is activated by oncogenic Ras-Raf signaling. Dmp1 expression is repressed by physiological mitogenic stimuli as well as by overexpressed E2F proteins; thus, it is a novel marker of cells that have exited from the cell cycle. Spontaneous and oncogene-induced tumor formation is accelerated in both Dmp1(+/-) and Dmp1(-/-) mice; the Dmp1(+/-) tumors often retain and express the wild-type allele; thus, Dmp1 is haplo-insufficient for tumor suppression. Tumors from Dmp1(+/-) and Dmp1(-/-) mice often retain wild-type Arf and p53, suggesting that Dmp1 is a physiological regulator of the Arf-p53 pathway. The human DMP1 (hDMP1) gene is located on chromosome 7q21, the locus of which is often deleted in myeloid leukemia and also in some types of solid tumors. Post-translational modification of Dmp1 and its role in human malignancy remain to be investigated.


Subject(s)
Transcription Factors/physiology , Tumor Suppressor Proteins/physiology , Animals , Cyclin D , Cyclin-Dependent Kinase Inhibitor p16/physiology , Cyclin-Dependent Kinases/physiology , Cyclins/physiology , E2F1 Transcription Factor/physiology , Genes, ras , Humans , Mice , Promoter Regions, Genetic , Transcription Factors/genetics , Tumor Suppressor Protein p53/physiology
4.
J Inherit Metab Dis ; 29(1): 76-85, 2006 Feb.
Article in English | MEDLINE | ID: mdl-16601872

ABSTRACT

North Carolina (NC) was the first US state to initiate universal tandem mass spectrometry (MS/MS) newborn screening. This began as a statewide pilot project in 1997 to determine the incidence and feasibility of screening for fatty acid oxidation, organic acid and selected amino acid disorders. The MS/MS analyses were done by a commercial laboratory and all follow-up and confirmatory testing was performed through the NC Newborn Screening (NBS) Program. In April 1999, the NC NBS Laboratory began the MS/MS analyses in-house. Between 28 July 1997 and 28 July 2005, 944,078 infants were screened and 219 diagnoses were confirmed on newborns with elevated screening results, for an overall incidence of 1:4,300. Ninety-nine infants were identified with fatty acid oxidation disorders, 58 with organic acidaemias and 62 with aminoacidopathies. Medium-chain acyl-CoA dehydrogenase deficiency, 3-methylcrotonyl-CoA carboxylase deficiency and disorders of phenylalanine metabolism were the most common disorders detected. Identification of affected infants has allowed retrospective testing of other family members, resulting in an additional 16 diagnoses. Seven neonates died from complications of their metabolic disorders/prematurity despite timely MS/MS screening. In addition, there were six infants who were not identified by elevated NBS results but who presented with symptoms later in infancy. The NC MS/MS NBS Program uses a two-tier system, categorizing results as either 'borderline' or 'diagnostic' elevated, for both the cutoffs and follow-up protocol. Infants with an initial borderline result had only a repeat screen. Infants with a diagnostic or two borderline results were referred for confirmatory testing. The positive predictive value of the NC MS/MS NBS for those infants requiring confirmatory testing was 53% for 2003 and 2004. The success of the NC MS/MS NBS Program in identifying infants with metabolic disorders was dependent on a comprehensive follow-up protocol integrating the public health laboratory and the academic metabolic centres.


Subject(s)
Metabolism, Inborn Errors/diagnosis , Metabolism, Inborn Errors/epidemiology , Neonatal Screening/methods , Neonatal Screening/standards , Spectrometry, Mass, Electrospray Ionization/methods , Spectrometry, Mass, Electrospray Ionization/standards , Blood Specimen Collection/methods , False Negative Reactions , Fatty Acids/metabolism , Female , Follow-Up Studies , Humans , Incidence , Infant, Newborn , Male , Neonatal Screening/trends , North Carolina , Phenylalanine/metabolism , Pilot Projects , Spectrometry, Mass, Electrospray Ionization/trends
5.
J Vet Pharmacol Ther ; 27(3): 139-46, 2004 Jun.
Article in English | MEDLINE | ID: mdl-15189299

ABSTRACT

The purpose of this study was to examine the allometric analysis of ciprofloxacin and enrofloxacin using pharmacokinetic data from the literature. The pharmacokinetic parameters used were half-life, clearance and volume of distribution. Relationships between body weight and the pharmacokinetic parameter were based on the empirical formula Y = aW(b), where Y is half-life, clearance or volume of distribution, W the body weight and a is an allometric coefficient (intercept) that is constant for a given drug. The exponential term b is a proportionality constant that describes the relationship between the pharmacokinetic parameter of interest and body weight. A total of 21 different species of animals were studied. Results of the allometric analyses indicated similarity between clearance and volume of distribution as they related to body weight for both drugs. Results of the current analyses indicate it is possible to use allometry to predict pharmacokinetic variables of enrofloxacin or ciprofloxacin based on body size of species. This could provide information on appropriate doses of ciprofloxacin and enrofloxacin for all species.


Subject(s)
Anti-Infective Agents/pharmacokinetics , Ciprofloxacin/pharmacokinetics , Fluoroquinolones/pharmacokinetics , Quinolones/pharmacokinetics , Animals , Enrofloxacin , Humans , Models, Biological , Species Specificity , Veterinary Drugs/pharmacokinetics
6.
J Inherit Metab Dis ; 26(1): 25-35, 2003.
Article in English | MEDLINE | ID: mdl-12872837

ABSTRACT

Since the addition of tandem mass spectrometry (MS/MS) to the North Carolina Newborn Screening Program, 20 infants with two consecutive elevated 3-hydroxyisovalerylcarnitine (C5OH) levels have been evaluated for evidence of inborn errors of metabolism associated with this metabolite. Ten of these 20 infants had significant concentrations of both 3-hydroxyisovaleric acid and 3-methylcrotonylglycine in their urine, suggestive of 3-methylcrotonyl-CoA carboxylase (3-MCC) deficiency. Four of these 10 were infants whose abnormal metabolites were found to be of maternal origin. Of 8 patients with probable 3-MCC deficiency, 7 have been tested and found to have the enzyme deficiency confirmed in lymphoblasts or cultured fibroblasts; one of these 7 infants had only marginally decreased 3-MCC activity in lymphocytes but deficient 3-MCC in fibroblasts. We estimate the incidence of 3-MCC deficiency at 1:64000 live births in North Carolina. We conclude that MS/MS newborn screening will detect additional inborn errors of metabolism, such as 3-MCC deficiency, not traditionally associated with newborn screening. The evaluation of newborns with two abnormally elevated C5OH levels on MS/MS newborn screening should include, at least, urine organic acid analysis by capillary GC-MS and a plasma acylcarnitine profile by MS/MS. Long-term follow-up is needed to determine the outcome of presymptomatically diagnosed patients with 3-MCC deficiency by MS/MS newborn screening.


Subject(s)
Carbon-Carbon Ligases/deficiency , Carbon-Carbon Ligases/genetics , Carnitine/analogs & derivatives , Genetic Testing/methods , Metabolism, Inborn Errors/genetics , Acids/urine , Carnitine/urine , Female , Humans , Infant, Newborn , Lymphocytes/enzymology , Male , Mass Spectrometry , Metabolism, Inborn Errors/epidemiology , Neonatal Screening , North Carolina/epidemiology , Pilot Projects
7.
J Appl Physiol (1985) ; 91(5): 2342-50, 2001 Nov.
Article in English | MEDLINE | ID: mdl-11641379

ABSTRACT

The rostral fastigial nucleus (FNr) of the cerebellum facilitates the respiratory response to hypercapnia. We hypothesized that some FNr sites are chemosensitive to focal tissue acidosis and contribute, at least partially, to respiratory modulation. Minute ventilation (VE) was recorded in 21 anesthetized and spontaneously breathing rats. Acetazolamide (AZ; 50 microM) was microinjected unilaterally into the FNr while an isocapnic condition was maintained throughout the experiment. AZ (1 or 20 nl) injection into the FNr significantly elevated VE (46.0 +/- 6.7%; P < 0.05), primarily via an increase in tidal volume (31.7 +/- 3.8%; P < 0.05), with little effect on arterial blood pressure. This augmented ventilatory response was initiated at 6.3 +/- 0.8 min and reached the peak at 19.7 +/- 4.1 min after AZ administration. The same dose of AZ delivered into the interposed and lateral cerebellar nuclei, or vehicle injection into the FNr, failed to elicit detectable cardiorespiratory responses. To determine whether the ventilatory response to AZ injection into the FNr resulted from an increase in respiratory central drive, the minute phrenic nerve activity (MPN) was recorded in seven paralyzed and ventilated rats. Similar to VE, MPN was increased by 38.9 +/- 8.9% (P < 0.05) after AZ administration. Our results suggest that elevation of CO2/H+ within the FNr facilitates respiratory output, supporting the presence of ventilatory chemoreception in rat FNr.


Subject(s)
Acetazolamide/pharmacology , Carbonic Anhydrase Inhibitors/pharmacology , Cerebellar Nuclei/physiology , Respiratory Mechanics/drug effects , Acetazolamide/administration & dosage , Animals , Carbonic Anhydrase Inhibitors/administration & dosage , Chemoreceptor Cells/drug effects , Male , Microinjections , Oxygen Consumption , Phrenic Nerve/physiology , Rats , Rats, Sprague-Dawley , Respiratory Function Tests , Stimulation, Chemical
8.
J Appl Physiol (1985) ; 91(4): 1713-22, 2001 Oct.
Article in English | MEDLINE | ID: mdl-11568155

ABSTRACT

Electrical stimulation of the rostral fastigial nucleus (FNr) alters respiration via activation of local neurons. We hypothesized that this FNr-mediated respiratory response was dependent on the integrity of the nucleus gigantocellularis of the medulla (NGC). Electrical stimulation of the FNr in 15 anesthetized and tracheotomized spontaneously breathing rats significantly altered ventilation by 35.2 +/- 11.0% (P < 0.01) with the major effect being excitatory (78%). This respiratory response did not significantly differ from control after lesions of the NGC via bilateral microinjection of kainic or ibotenic acid (4.5 +/- 1.9%; P > 0.05) but persisted in sham controls. Eight other rats, in which horseradish peroxidase (HRP) solution was previously microinjected into the left NGC, served as nonstimulation controls or were exposed to either 15-min repeated electrical stimulation of the right FNr or hypercapnia for 90 min. Histochemical and immunocytochemical data showed that the right FNr contained clustered HRP-labeled neurons, most of which were double labeled with c-Fos immunoreactivity in both electrically and CO(2)-stimulated rats. We conclude that the NGC receives monosynaptic FNr inputs and is required for fully expressing FNr-mediated respiratory responses.


Subject(s)
Medulla Oblongata/physiology , Respiratory Mechanics/physiology , Animals , Electric Stimulation , Excitatory Amino Acid Agonists/administration & dosage , Excitatory Amino Acid Agonists/pharmacology , Horseradish Peroxidase , Immunohistochemistry , Kainic Acid/administration & dosage , Kainic Acid/pharmacology , Male , Medulla Oblongata/anatomy & histology , Microinjections , Neural Pathways/drug effects , Neural Pathways/physiology , Proto-Oncogene Proteins c-fos/metabolism , Rats , Rats, Sprague-Dawley , Respiratory Mechanics/drug effects , Synapses/drug effects , Synapses/physiology
9.
J Virol ; 75(14): 6558-65, 2001 Jul.
Article in English | MEDLINE | ID: mdl-11413323

ABSTRACT

Passive antibody prophylaxis against human immunodeficiency virus type 1 (HIV-1) has been accomplished in primates, suggesting that this strategy may prove useful in humans. While antibody specificity is crucial for neutralization, other antibody characteristics, such as subclass, have not been explored. Our objective was to compare the efficiencies of immunoglobulin G (IgG) subclasses from polyclonal human HIV immune globulin (HIVIG) in the neutralization of HIV-1 strains differing in coreceptor tropism. IgG1, IgG2, and IgG3 were enriched from HIVIG by using protein A-Sepharose. All three subclasses bound major HIV-1 proteins, as shown by Western blot assay and enzyme-linked immunosorbent assay. In HIV-1 fusion assays using X4, R5, or X4R5 envelope-expressing effector cells, IgG3 more efficiently blocked fusion. In neutralization assays with cell-free viruses using X4 (LAI, IIIB), R5 (BaL), and X4R5 (DH123), a similar hierarchy of neutralization was found: IgG3 > IgG1 > IgG2. IgG3 has a longer, more flexible hinge region than the other subclasses. To test whether this is important, IgG1 and IgG3 were digested with pepsin to generate F(ab')(2) fragments or with papain to generate Fab fragments. IgG3 F(ab')(2) fragments were still more efficient in neutralization than F(ab')(2) of IgG1. However, Fab fragments of IgG3 and IgG1 demonstrated equivalent neutralization capacities and the IgG3 advantage was lost. These results suggest that the IgG3 hinge region confers enhanced HIV-neutralizing ability. Enrichment and stabilization of IgG3 may therefore lead to improved HIVIG preparations. The results of this study have implications for the improvement of passive immunization with polyclonal or monoclonal antibodies and suggest that HIV-1 vaccines which induce high-titer IgG3 responses could be advantageous.


Subject(s)
Antibodies, Viral/immunology , HIV Infections/prevention & control , HIV-1/immunology , Immunoglobulin G/immunology , Humans , Immunoglobulin Fab Fragments/immunology , Neutralization Tests
10.
Am J Hum Genet ; 68(6): 1408-18, 2001 Jun.
Article in English | MEDLINE | ID: mdl-11349232

ABSTRACT

Medium-chain acyl-CoA dehydrogenase (MCAD) deficiency is the most frequently diagnosed mitochondrial beta-oxidation defect, and it is potentially fatal. Eighty percent of patients are homozygous for a common mutation, 985A-->G, and a further 18% have this mutation in only one disease allele. In addition, a large number of rare disease-causing mutations have been identified and characterized. There is no clear genotype-phenotype correlation. High 985A-->G carrier frequencies in populations of European descent and the usual avoidance of recurrent disease episodes by patients diagnosed with MCAD deficiency who comply with a simple dietary treatment suggest that MCAD deficiency is a candidate in prospective screening of newborns. Therefore, several such screening programs employing analysis of acylcarnitines in blood spots by tandem mass spectrometry (MS/MS) are currently used worldwide. No validation of this method by mutation analysis has yet been reported. We investigated for MCAD mutations in newborns from US populations who had been identified by prospective MS/MS-based screening of 930,078 blood spots. An MCAD-deficiency frequency of 1/15,001 was observed. Our mutation analysis shows that the MS/MS-based method is excellent for detection of MCAD deficiency but that the frequency of the 985A-->G mutant allele in newborns with a positive acylcarnitine profile is much lower than that observed in clinically affected patients. Our identification of a new mutation, 199T-->C, which has never been observed in patients with clinically manifested disease but was present in a large proportion of the acylcarnitine-positive samples, may explain this skewed ratio. Overexpression experiments showed that this is a mild folding mutation that exhibits decreased levels of enzyme activity only under stringent conditions. A carrier frequency of 1/500 in the general population makes the 199T-->C mutation one of the three most prevalent mutations in the enzymes of fatty-acid oxidation.


Subject(s)
Acyl-CoA Dehydrogenases/deficiency , Acyl-CoA Dehydrogenases/genetics , Carnitine/analogs & derivatives , Carnitine/blood , Genetic Testing/methods , Mutation, Missense/genetics , Acyl-CoA Dehydrogenase , Acyl-CoA Dehydrogenases/chemistry , Acyl-CoA Dehydrogenases/metabolism , Alleles , Chaperonin 10/genetics , Chaperonin 10/metabolism , Chaperonin 60/genetics , Chaperonin 60/metabolism , DNA Mutational Analysis , Enzyme Stability , Escherichia coli/genetics , Exons/genetics , Haplotypes/genetics , Heterozygote , Homozygote , Humans , Infant, Newborn , Mass Spectrometry , Molecular Sequence Data , Mutagenesis, Site-Directed/genetics , Polymorphism, Single Nucleotide/genetics , Protein Folding , Recombinant Proteins/chemistry , Recombinant Proteins/genetics , Recombinant Proteins/metabolism , Reproducibility of Results , Temperature
11.
J Bone Joint Surg Am ; 83(4): 560-5, 2001 Apr.
Article in English | MEDLINE | ID: mdl-11315785

ABSTRACT

BACKGROUND: Fungal infections of the spine are noncaseating, acid-fast-negative infections that occur primarily as opportunistic infections in immunocompromised patients. We analyzed eleven patients with spinal osteomyelitis caused by a fungus, and we developed suggestions for treatment. METHODS: All patients with a fungal infection of the spine treated by the authors over a sixteen-year period at three teaching institutions were evaluated. There was a total of eleven patients. Medical records and roentgenograms were available for every patient. Long-term follow-up of the nine surviving patients was performed by direct examination by the authors or by the patient's primary physician. RESULTS: For ten of the eleven patients, the average delay in the diagnosis was ninety-nine days. Nine patients were immunocompromised secondary to diabetes mellitus, corticosteroid use, chemotherapy for a tumor, or malnutrition. The sources of the spinal infections included direct implantation from trauma (one patient), hematogenous spread (four patients), and local extension (two patients). The infection followed elective spine surgery in three patients, and the cause was unknown in one. Paralysis secondary to the spine infection developed in eight patients. Ten patients were treated with surgical debridement. All eleven patients were treated with systemic antifungal medications for a minimum of six weeks. One patient died of generalized sepsis at thirty-three days, and another patient died of gastrointestinal hemorrhage at five months. After an average of 6.3 years of follow-up, the infection had resolved in all nine surviving patients. CONCLUSIONS: Treatment of fungal spondylitis is often delayed because of difficulty with the diagnosis. Delay in the diagnosis led to poorer results in terms of neurologic recovery in our study. Performing fungal cultures whenever a spinal infection is suspected might hasten the diagnosis. Patients should be given a guarded prognosis and informed of the many possible complications of the disease.


Subject(s)
Mycoses/epidemiology , Osteomyelitis/microbiology , Spinal Diseases/microbiology , Female , Follow-Up Studies , Humans , Immunocompromised Host , Male , Middle Aged , Mycoses/immunology , Mycoses/therapy , Osteomyelitis/epidemiology , Osteomyelitis/immunology , Osteomyelitis/therapy , Retrospective Studies , Risk Factors , Spinal Diseases/epidemiology , Spinal Diseases/immunology , Spinal Diseases/therapy , Time Factors
12.
J Vet Pharmacol Ther ; 23(5): 293-302, 2000 Oct.
Article in English | MEDLINE | ID: mdl-11107003

ABSTRACT

Plasma, urine, and skin drug concentrations were determined for dogs (n=12) given five daily oral doses of marbofloxacin (MAR) (2.75 mg/kg), enrofloxacin (ENR) (5.0 mg/kg) or difloxacin (DIF) (5.0 mg/kg). Concentrations of the active metabolite of ENR, ciprofloxacin (CIP), were also determined. The three-period, three-treatment crossover experimental design included a 21-day washout period between treatments. Area under the plasma drug concentration vs. time curve (AUC0-last, microg/mLxh of MAR was greater than for ENR, CIP, ENR/CIP combined, and DIF. Maximum concentration (Cmax) of MAR was greater than ENR, CIP, and DIF. Time of maximum plasma concentration (Tmax) was similar for MAR and DIF; Tmax occurred earlier for ENR and later for CIP. Plasma half-life (t1/2) of MAR was longer than for ENR, CIP, and DIF. Urine concentrations of DIF were less than MAR or ENR/CIP combined, but urine concentrations of MAR and ENR/CIP combined did not differ. DIF skin concentrations were less than the concentrations of MAR or ENR/CIP combined 2 h after dosing, but skin concentrations of MAR and ENR/CIP combined did not differ.


Subject(s)
Anti-Infective Agents/pharmacokinetics , Ciprofloxacin/analogs & derivatives , Dogs/metabolism , Fluoroquinolones , Administration, Oral , Animals , Anti-Infective Agents/administration & dosage , Anti-Infective Agents/blood , Anti-Infective Agents/urine , Area Under Curve , Ciprofloxacin/metabolism , Ciprofloxacin/pharmacokinetics , Cross-Over Studies , Enrofloxacin , Female , Quinolones/pharmacokinetics , Skin/metabolism
13.
Can J Vet Res ; 64(4): 208-11, 2000 Oct.
Article in English | MEDLINE | ID: mdl-11041497

ABSTRACT

The effect of yohimbine pretreatment on gastric emptying of a liquid marker in horses was evaluated by measuring serum concentrations of acetaminophen. Gastric emptying was determined in normal, fasted horses, in horses given endotoxin (E. coli 055 B5; 0.2 microg/kg) intravenously, and in horses given yohimbine (0.25 mg/kg, IV, over 30 minutes) plus endotoxin. Acetaminophen (20 mg/kg) was given by stomach tube 15 minutes after the endotoxin infusion. Blood samples for acetaminophen analysis were collected, and time to reach the peak serum concentration (Tmax), the maximum serum concentration (Cmax) and the area under the acetaminophen serum concentration versus time curve (AUC) were determined for each treatment group. Endotoxin significantly increased Tmax, indicating a profound delay in gastric emptying and yohimbine pretreatment significantly (P < or = 0.05) prevented this effect.


Subject(s)
Adrenergic alpha-Antagonists/pharmacology , Endotoxins/pharmacology , Gastric Emptying/drug effects , Horses/physiology , Yohimbine/pharmacology , Acetaminophen/pharmacokinetics , Adrenergic alpha-Antagonists/pharmacokinetics , Animals , Anti-Inflammatory Agents, Non-Steroidal/pharmacokinetics , Area Under Curve , Drug Interactions , Female , Yohimbine/pharmacokinetics
14.
J Appl Physiol (1985) ; 89(3): 996-1004, 2000 Sep.
Article in English | MEDLINE | ID: mdl-10956343

ABSTRACT

The present study was undertaken to determine what roles the various cerebellar deep nuclei (CDN) play in modulation of respiration, especially during chemical challenges. Experiments were carried out in 12 anesthetized, tracheotomized, paralyzed, and ventilated rats. The integrated phrenic nerve activity (integralPN) was recorded as an index of respiratory motor output. A stimulating electrode was sequentially placed into the fastigial nucleus (FN), the interposed nucleus, and the lateral nucleus. Only stimulation of the FN significantly altered respiration, primarily via increasing respiratory frequency associated with a pressor response. The evoked respiratory responses persisted after blocking the pressor response via pretreatment with phenoxybenzamine or use of transient stimulation (<2 s) but were abolished by microinjection of kainic acid into the FN. To test the involvement of FN neurons in respiratory chemoreflexes, ventilation with hypercapnic gases mixture and intravenous injection of sodium cyanide were applied before and after CDN lesions induced by kainic acid. CDN lesions did not significantly alter eupneic breathing, but FN lesions attenuated the respiratory response to hypercapnia and sodium cyanide. We conclude that, with respect to the CDN in the rat, FN neurons uniquely modulate respiration independent of cardiovascular effects and facilitate respiratory responses mediated by activation of CO(2) and O(2) receptors.


Subject(s)
Cerebellar Nuclei/physiology , Respiratory Muscles/physiology , Animals , Cerebellar Nuclei/cytology , Electric Stimulation , Hypercapnia/physiopathology , Hypertension/physiopathology , Neurons/physiology , Phrenic Nerve/physiology , Rats , Rats, Sprague-Dawley , Reference Values , Respiration/drug effects , Respiratory Physiological Phenomena , Sodium Cyanide/pharmacology
16.
AORN J ; 71(1): 193-8, 2000 Jan.
Article in English | MEDLINE | ID: mdl-10686651

ABSTRACT

Resorbable fixation technology offers several benefits, including easily cut and shaped plates, strong and predictable resorption qualities, and improved patient acceptance and expectations. Moreover, resorbable fixation implants can be completely reabsorbed into the body, eliminating the need for subsequent removal. This article describes the use of this innovative technology in orthognathic surgery, including preoperative and postoperative patient needs, intraoperative patient care, and potential complications.


Subject(s)
Absorbable Implants , Internal Fixators , Maxillofacial Prosthesis Implantation/instrumentation , Maxillofacial Prosthesis Implantation/nursing , Perioperative Nursing/methods , Elective Surgical Procedures , Humans , Lactic Acid , Polyesters , Polyglycolic Acid , Polymers
17.
Appl Opt ; 39(29): 5337-46, 2000 Oct 10.
Article in English | MEDLINE | ID: mdl-18354530

ABSTRACT

We demonstrate a simple all-optical realization of programmable edge enhancement and edge-enhanced correlation using novel photorefractive polymers. We show that the higher non-Bragg order in a two-beam coupling scheme contains the edge enhancement of the object when placed in the path of one of the incident beams. Also, this arrangement provides a scheme for writing joint transform correlation dynamic holograms, which can be read by a third beam. The correlation is edge enhanced, and the correlation peak increases with the applied bias voltage. Numerical results without and with beam fanning are presented. Theoretical predictions are reconciled with experimental results.

18.
Vet Surg ; 28(5): 375-9, 1999.
Article in English | MEDLINE | ID: mdl-10493642

ABSTRACT

OBJECTIVE: The effect of sedation on gastric emptying was evaluated in six ponies by monitoring serum concentrations of acetaminophen (AP) after intragastric administration. EXPERIMENTAL DESIGN: Prospective randomized experimental study. ANIMALS: Six adult ponies, 135 to 275 kg. METHODS: Fifteen minutes after the intravenous administration of xylazine (1 mg/kg), butorphanol (0.05 mg/kg), acepromazine (0.05 mg/kg) or saline, ponies were given AP (20 mg/kg in 350 mL water) by stomach tube. Blood for AP analysis was collected at baseline and 15, 30, 45, 75, 90, 105, and 120 minutes after AP administration. The time (Tmax) to reach peak serum concentration (Cmax), and the area under the AP serum concentration versus time curve (AUC) were determined for each treatment group. RESULTS: Tmax was 31 mins in the control group, and this increased significantly (P<.05) after sedation. Cmax decreased (P<.05) after xylazine administration, and AUC decreased (P<.05) after acepromazine. CONCLUSIONS: This study indicated that sedation has a significant effect on the gastric emptying rate of a liquid in ponies.


Subject(s)
Acetaminophen/pharmacokinetics , Analgesics, Non-Narcotic/pharmacokinetics , Gastric Emptying/drug effects , Horses/metabolism , Hypnotics and Sedatives/pharmacology , Acepromazine/pharmacology , Acetaminophen/administration & dosage , Acetaminophen/blood , Adrenergic alpha-Agonists/pharmacology , Analgesics, Non-Narcotic/administration & dosage , Analgesics, Non-Narcotic/blood , Analgesics, Opioid/pharmacology , Animals , Antipsychotic Agents/pharmacology , Area Under Curve , Butorphanol/pharmacology , Female , Intubation, Gastrointestinal/veterinary , Prospective Studies , Xylazine/pharmacology
19.
Cancer Chemother Pharmacol ; 44(1): 74-80, 1999.
Article in English | MEDLINE | ID: mdl-10367752

ABSTRACT

PURPOSE: To determine whether tamoxifen plasma concentrations capable of blocking P-glycoprotein (Pgp) in vitro can be safely achieved in dogs and whether doxorubicin pharmacokinetic alterations occur when tamoxifen is coadministered. METHODS: Tamoxifen dose escalation studies were conducted in 7 normal dogs and in 19 tumor-bearing dogs receiving full-dose chemotherapy. Plasma tamoxifen and serum doxorubicin disposition were analyzed for putative drug interactions. RESULTS: Steady-state plasma concentrations of tamoxifen and N-desmethyl tamoxifen (NDMT) were 5-10 microM following oral tamoxifen administration at 600 mg/m2 every 12 h for 7 days to normal and tumor-bearing dogs. Mild-moderate gastrointestinal toxicity (diarrhea, anorexia) and reversible neurotoxicity were observed in dogs receiving chemotherapy plus high-dose tamoxifen. Myelosuppression was not affected by combined treatment in tumor-bearing dogs. High-dose tamoxifen decreased the clearance and volume of distribution of full-dose doxorubicin. CONCLUSIONS: Concentrations of tamoxifen/ NDMT sufficient to inhibit Pgp may be achieved in dogs receiving full-dose chemotherapy with a moderate but acceptable increase in gastrointestinal toxicity. Tamoxifen affects doxorubicin metabolism in dogs at high doses resulting in increased serum exposure. Pharmacologic manipulation of Pgp expression or function in normal and tumor tissue in dogs may facilitate investigation of novel anticancer treatment strategies in humans.


Subject(s)
Antineoplastic Agents, Hormonal/administration & dosage , Antineoplastic Agents, Hormonal/pharmacokinetics , Doxorubicin/pharmacokinetics , Drug Resistance, Multiple , Tamoxifen/administration & dosage , Tamoxifen/pharmacokinetics , ATP Binding Cassette Transporter, Subfamily B, Member 1/biosynthesis , ATP Binding Cassette Transporter, Subfamily B, Member 1/drug effects , Animals , Antineoplastic Agents, Hormonal/adverse effects , Digestive System/drug effects , Dogs , Dose-Response Relationship, Drug , Doxorubicin/adverse effects , Drug Interactions , Female , Male , Neoplasms, Experimental/metabolism , Tamoxifen/adverse effects , Tissue Distribution
20.
Anat Rec ; 254(4): 542-8, 1999 04 01.
Article in English | MEDLINE | ID: mdl-10203261

ABSTRACT

We have reported that the phrenic neurogram (PN) is modulated by stimulation of the fastigial nucleus (FN) of the cerebellum. The present study was undertaken to search for brainstem site(s) involved in the FN efferent pathway to modulate phrenic nerve activities. Experiments were performed on 35 anesthetized, paralyzed, and ventilated cats, using the PN as the index of the respiratory motor output. Results showed that bilateral electrolytic lesions of the red nucleus (RN), the paramedian reticular nucleus (PRN), or the pontine respiratory group (PRG) had little effect on the ability of FN stimulation to modulate the respiratory output. However, the modulation was abolished by bilateral electrolytic lesions of the Bötzinger complex (BötC). Further studies showed that bilateral chemical inactivation of BötC neurons produced by topical microinjection of kainic acid or cobalt chloride failed to abolish the modulation. We concluded that fibers of passage, not synapses or cell bodies in the BötC, were involved in the modulatory effect of FN stimulation on the PN. The RN, PRN, and PRG appear not to be important in the neural circuitry responsible for the FN modulation of the phrenic activity.


Subject(s)
Cerebellar Nuclei/physiology , Respiration , Animals , Cats , Cerebellar Nuclei/drug effects , Cobalt/pharmacology , Electric Stimulation , Female , Kainic Acid/pharmacology , Male , Phrenic Nerve/metabolism , Time Factors
SELECTION OF CITATIONS
SEARCH DETAIL
...